Dr. Barry Dworkin

BioNTech founders say their company is working on adapting mRNA technology to produce cancer-fighting vaccines. They hope to have something by 2030.

Medical Mythbusting Commentary for October 18, 2022

Source:
Vaccines to treat cancer possible by 2030, say BioNTech founders

Related posts:

  1. New biotherapeutic cancer treatment centre an excellent addition to novel therapeutic solutions
  2. Vaccine trial suspension is an expected response after reports of a single adverse event. It shows that proper protocols are being followed to determine if it is related to the vaccine. Phase 3 trials are designed to determine how larger and more diverse population groups respond.
  3. Retracted Canadian study that reported 1/1000 risk of myocarditis from mRNA vaccine weaponized by anti-vaccination websites despite data correction by the authors to 1/25,000. Review system worked to uncover error but damage now done.
  4. A vaccine for Lyme disease is in its Phase 3 trial. Results to date show efficacy and safety. If trial is successful, official authorization expected in 2025.